Drugs / ADSC01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06574581 | Aug 2024 → Apr 2027 expected | connective tissue disorder, interstitial lung disease | China Medical University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADSC01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06574581 ↗ |
| Modality | Cell therapy | “stem cell therapy” NCT06574581 ↗ |
| Route | Intravenous | “intravenous transfusion with allogenic AD-MSC” NCT06574581 ↗ |